Advances in using PARP inhibitors to treat cancer
<p>Abstract</p> <p>The poly (ADP-ribose) polymerase (PARP) family of enzymes plays a critical role in the maintenance of DNA integrity as part of the base excision pathway of DNA repair. PARP1 is overexpressed in a variety of cancers, and its expression has been associated with ove...
Main Authors: | Kummar Shivaani, Chen Alice, Parchment Ralph E, Kinders Robert J, Ji Jay, Tomaszewski Joseph E, Doroshow James H |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-03-01
|
Series: | BMC Medicine |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1741-7015/10/25 |
Similar Items
-
Resistance to PARP-inhibitors in Cancer Therapy
by: Alicia eMontoni, et al.
Published: (2013-02-01) -
The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
by: Jaromir Hunia, et al.
Published: (2022-12-01) -
Pharmacologic Induction of BRCAness in <i>BRCA</i>-Proficient Cancers: Expanding PARP Inhibitor Use
by: Rachel Abbotts, et al.
Published: (2022-05-01) -
Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality
by: Bac Viet Le, et al.
Published: (2022-11-01) -
In Silico Screening Identifies a Novel Potential PARP1 Inhibitor Targeting Synthetic Lethality in Cancer Treatment
by: Jian Li, et al.
Published: (2016-02-01)